Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The new French National Cancer Institute (INCa) has brought cancer care, research and policy in France together for the first time. Three years after its conception, and one year after its inauguration, this article charts its aims and structure.
There are now many genetic tests that provide information about cancer risk. How should clinicians and policy makers ensure that the clinical uses of these tests maximize benefit and minimize harm?
How do cancer patients decide whether to take part in clinical trials? Gordon Jayson and John Harris discuss the rules and realities concerning confidentiality, informed consent and protection of patients.
Accessible information about the presence and effect of specific mutations in cancer-causing genes is essential, but keeping track of these mutations is not simple. This article, using p53 as an example, highlights the difficulties involved in maintaining mutation databases.
